3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 20...(nformation please contact: Investor C...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Date:3/11/2009
nformation, please contact: Investor Contact: Bo Tan, CFO 3SBio Inc. Tel: +86-24-2581-1820 Email: Tanbo@3sbio.com Investor Relations (China): Peter Schmidt FD Beijing Tel: +86-10-8591-1953 Email: Peter.schmidt@fd.com Investor Relations (US): Evan Smith / John Capodanno FD US Tel: +1-212-850-5600
'/>"/>
| SOURCE 3SBio Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting
Post Your Comments:
Breaking Biology Technology:Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3Biomatrica Launches SampleWare 3.1 2Biomatrica Launches SampleWare 3.1 3
Other Biology Technology:SleepQuest Compliance Again Doubles Industry Average 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 2AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 3
Breaking Biology News(10 mins):Copying mother nature's designs 2University of Washington professor garners Avanti Young Investigator Award 2Vermicompost from pig manure grows healthy hibiscus 2BMP Sunstone Announces November Investor Conference Participation 14664 1BMP Sunstone Announces November Investor Conference Participation 14664 2CCBR SYNARC Expands Electronic Data Capture Capabilities 5879 1CCBR SYNARC Expands Electronic Data Capture Capabilities 5879 2Stryker Announces Change in Chairman of the Board of Directors 5876 1Stryker Announces Change in Chairman of the Board of Directors 5876 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |